These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16640098)

  • 21. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.
    Antinori A; Liuzzi G; Cingolani A; Bertoli A; Di Giambenedetto S; Trotta MP; Rizzo MG; Girardi E; De Luca A; Perno CF
    AIDS; 2001 Nov; 15(17):2325-7. PubMed ID: 11698709
    [No Abstract]   [Full Text] [Related]  

  • 22. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
    Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
    Violin M; Forbici F; Cozzi-Lepri A; Velleca R; Bertoli A; Riva C; Giannella S; Manconi PE; Lazzarin A; Pasquinucci S; Tacconi L; Carnevale G; Mazzotta F; Bonazzi L; Montroni M; Chirianni A; Capobianchi M; Ippolito G; Moroni M; Perno CF; D'Arminio-Monforte A;
    J Biol Regul Homeost Agents; 2002; 16(1):37-43. PubMed ID: 12003172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the genotypic pattern of HIV-1 resistance in AIDS patients failing antiretroviral therapy.
    Bahia F; Pedroso C; Netto EM; Figueiredo R; Pinto Neto L; Brites C
    Braz J Infect Dis; 2004 Aug; 8(4):281-9. PubMed ID: 15565258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.
    Medeiros MS; Arruda EA; Guerrant RL; Brown CC; Lima AA
    Braz J Infect Dis; 2007 Oct; 11(5):451-5. PubMed ID: 17962868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil.
    Toledo PV; Carvalho DS; Romagnoli L; Marcinko G; Cunha CA; Souza MN; Brindeiro R; Queiroz-Telles Fd
    Braz J Infect Dis; 2010; 14(4):360-71. PubMed ID: 20963321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.
    Al Mazari A; Zomaya AY; Charleston M; Salem H; Maher A; Garsia RJ
    Curr HIV Res; 2007 Jul; 5(4):430-9. PubMed ID: 17627506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco.
    Cavalcanti AM; Brito AM; Salustiano DM; Lima KO; Silva SP; Diaz RS; Lacerda HR
    Mem Inst Oswaldo Cruz; 2012 Jun; 107(4):450-7. PubMed ID: 22666853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection.
    Tamalet C; Pasquier C; Yahi N; Colson P; Poizot-Martin I; Lepeu G; Gallais H; Massip P; Puel J; Izopet J
    J Med Virol; 2000 Jun; 61(2):181-6. PubMed ID: 10797372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy.
    Angelis DS; Tateno AF; Diaz RS; Succi RC; Pannuti CS; Gouvea Ade F; Machado DM
    Braz J Infect Dis; 2011; 15(1):60-5. PubMed ID: 21412591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.